Nicholas Patrick McAndrew, MD, MSCE
Articles
CDK4/6 Inhibitors Are Tested in Adjuvant Setting
February 06, 2019
Article
Although ET significantly reduces the risk of HRpositive/ HER2- negative early breast cancer, the cumulative risk of distant recurrence has remained steady for decades.